Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
28-day randomized placebo-controlled study of SB-656933 in cystic fibrosis
2010-018738-27Phase 2Completed
- Sponsor
- GSK
- Start
- Mar 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in cystic fibrosis (CF) comparing SB-656933 with Placebo (2 arms). Primary endpoint: Safety and tolerability of SB-656933. Started Mar 2010; status: completed.
02
Drugs
elubrixin
03
Conditions
cystic fibrosis (CF)
Beyond the preview
Go deeper on 2010-018738-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-018738-27.